The Federal Reserve releases its Beige Book on the economy at 2 p.m.

“The big focus of recently is going to be the Beige Book,” said Peter Cardillo, chief market economist at Rockwell Global Capital. “Although I think the Beige Book will probably basically indicate the concerns of the past, if it should be non-friendly that could accelerate the downward trend.”

Growth in the U.S. services sector accelerated modestly in February, lifted by improvements in new business, Markit said. The final reading of its Purchasing Managers Index for the services sector climbed to 57.1 in February, its highest level since October. The reading was roughly even with the preliminary read of 57.0 but up from the 54.2 recorded in January.

Insights about U.S. Stocks that are active during the current trade, are depicted underneath:

Cytori Therapeutics Inc (NASDAQ:CYTX)’s shares dipped -6.67%, and is now trading at $1.12. The Stock is active as 2.76M shares changed hands versus its average volume of 5.09M shares.

Today, Cytori Therapeutics Inc., offered a business and financial performance update in its presentation at the Cowen and Corporation 35th Annual Health Care Conference in Boston recently. The corporate presentation comprises certain top-line preliminary unaudited financial results for the quarter and full year ended December 31, 2014 and select performance guidance for the full-year 2015.

• Preliminary cash and debt balances at December 31, 2014 of about $14.6 million and $25 million, respectively.
• Preliminary Q4 and full-year 2014 operating cash burn of about $4.9 million and $30.3 million; respectively.
• Preliminary Q4 and full-year 2014 product proceed of about $2.5 million and $5.0 million, respectively.
• Preliminary Q4 and full-year 2014 contribution (profit/loss) from our sales and marketing organization, not including share based compensation, of a profit of about $44 thousand and a loss of about $3.9 million, respectively.
• Preliminary Q4 and full-year 2014 contract proceed of about $1.3 million and $2.6 million, respectively.
• Estimation of 2015 operating cash burn of about $25 million.
• Full-year 2015 product proceed predictable to be within a range from $5 million and $8 million.
• Full-year 2015 contribution (profit/loss) from our sales and marketing organization, not including share based compensation, predictable to be a profit ranging from $100 thousand and $300 thousand.
• Full-year 2015 contract proceed predictable to be within a range from $6 million and $8 million.

The Corporation will declare complete financial and operating results of its fourth quarter and the full-year ended December 31, 2014, after the market closes on March 12, 2015. Details to be offered in the forthcoming days.

Cytori Therapeutics is a late stage cell therapy corporation developing autologous cell therapies from adipose tissue to treat a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair.

Atossa Genetics Inc (NASDAQ:ATOS), raised 6.58%, and is now trading at $2.09. The Stock is active as 2.43M shares changed hands versus its average volume of 1.77M shares.

Today, Atossa Genetics Inc., declared that it has begun to launch the ForeCYTE Breast Aspirator and Collection Kit within the European Union, focusing initially on The Netherlands, Germany, Switzerland, and the United Kingdom.

Dr. Steven Quay, Chairman, CEO & President of Atossa Genetics, commented, “Launching and commercializing the ForeCYTE device in the EU is one of our key objectives for 2015 and we are happy to declare that we have taken a noteworthy step forward in achieving this aim. We have accepted an initial order for ForeCYTE Breast Aspirators and Collection Kits from the University Medical Center Utrecht, The Netherlands, which will be fulfilled by our logistics provider, Rhenus Logistics, located in The Netherlands.”

In addition, various studies using Atossa’s ForeCYTE device are planned in each of these mentioned geographic areas.

Atossa is focused on four objectives in 2015 for the benefit of all of our stakeholders, especially women with serious breast disease:

• Launching and commercializing the CE-marked ForeCYTE Breast Aspirator in the EU, and other non-U.S. markets;
• Achieving top-line combined gross proceed of $8.0 million from medical device sales and laboratory services, counting our pharmacogenomics test offering, and;
• Initiating pharmaceutical clinical trials in women for the treatment of serious breast diseases via local delivery of pharmaceuticals, potentially reducing systemic adverse events.

Launching the ForeCYTE device in the EU significantly advances our key objectives. We look forward to announcing additional progress in each of these important objectives over the coming weeks and months.”

Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its partner, The National Reference Laboratory for Breast Health, Inc.

Bob Evans Farms Inc (NASDAQ:BOBE), declined -22.59%, and is now trading at $46.20. The Stock is active as 3.28M shares changed hands versus its average volume of 272,297.00 shares.

Bob Evans Farms Inc., offered an update concerning a range of planned initiatives the Corporation has been evaluating. The Corporation also stated its financial results for the fiscal 2015 third quarter ended Friday, January 23, 2015.

Third-quarter fiscal 2015 results:

On a GAAP basis, the Corporation stated net revenue of $5.9 million, or $0.25 per diluted share, contrast with net revenue of $6.2 million, or $0.24 per diluted share, in the comparable period last year. On a non-GAAP basis, net revenue was $14.3 million, or $0.60 per diluted share, contrast with net revenue of $8.2 million, or $0.31 per diluted share, in the comparable period last year.

Bob Evans Farms, Inc. operates as a full-service restaurant corporation in the United States. The corporation conducts its operations through Bob Evans Restaurants and BEF Foods segments.

Regions Financial Corp (NYSE:RF), dwindled -0.94 %, and is now trading at $9.53. The Stock is active as 2.99M shares changed hands versus its average volume of 17.59M shares.

Regions Financial Corp., formerly on February 27, declared that, as of 5:00 p.m., New York City time, on February 26, 2015 (the “Early Tender Date”), its wholly-owned partner, Regions Bank, had received tenders for an aggregate principal amount of about $324,537,000 of its outstanding 7.50% Subordinated Notes due 2018 in the cash tender offer declared on February 12, 2015. The tender offer, in which the Bank is offering to purchase up to $250 million aggregate principal amount of the Notes, is being made following the Offer to Purchase and the related Letter of Transmittal sent to holders of the Notes, each dated February 12, 2015.

Because the aggregate principal amount of Notes validly tendered and not validly withdrawn as of the Early Tender Date exceeded the Maximum Tender Amount, about 77.0% percent of Notes validly tendered as of the Early Tender Date will be accepted for payment in accordance with the proration procedures described in the Offer to Purchase.

Regions Financial Corporation (RF), with $120 billion in assets, is a member of the S&P 500 Index and is one of the nation’s largest full-service providers of consumer and commercial banking, wealth administration, mortgage, and insurance products and services.